Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totaling 482,725 shares, an increase of 94.2% from the December 15th total of 248,611 shares. Based on an average daily trading volume, of 835,806 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.9% of the shares of the stock are short sold. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 835,806 shares, the days-to-cover ratio is presently 0.6 days.

Klotho Neurosciences Stock Performance

KLTO stock traded up $0.03 during midday trading on Thursday, hitting $0.33. 1,228,116 shares of the stock were exchanged, compared to its average volume of 632,210. The stock’s 50-day moving average price is $0.41 and its 200-day moving average price is $0.65. The stock has a market cap of $23.92 million, a price-to-earnings ratio of -1.03 and a beta of 10.27. Klotho Neurosciences has a fifty-two week low of $0.11 and a fifty-two week high of $3.91.

Klotho Neurosciences (NASDAQ:KLTO) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share for the quarter.

Institutional Trading of Klotho Neurosciences

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC purchased a new position in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned about 0.05% of Klotho Neurosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 20.07% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.